Refine by
Cell Metric X Clone Imager Articles & Analysis
13 news found
CD BioSciences, a US-based biotechnology company focusing on the development of imaging technologies, is excited to announce the launch of its new Immune System Tissue Microarrays for the scientific community to study the complex interactions of the immune system in various tissues. These innovative products offer researchers a powerful tool to unravel the complexities of the immune system and ...
CD BioSciences, a US-based biotechnology company focusing on the development of imaging technologies, is pleased to announce the launch of its new line of Circulatory System Tissue Microarrays to the scientific community. This new product line offers researchers a powerful tool to study a wide range of diseases affecting the heart, blood vessels, and spleen. CD BioSciences is committed to ...
CD BioSciences, a US-based biotechnology company focusing on the development of imaging technologies, proudly announces an extensive portfolio of Nervous System Tissue Microarrays designed to support neuroscience research. This comprehensive collection provides researchers with a unique resource to study various neurological conditions and accelerate their investigations into neurological ...
Creative Biostructure, a leading provider of innovative imaging solutions, is pleased to announce the launch of its new Structured Illumination Microscopy (SIM) service. This cutting-edge imaging technique offers enhanced resolution and imaging capabilities, allowing researchers to visualize biological samples with unprecedented detail. Structured Illumination Microscopy is a super-resolution ...
CD BioSciences, a US-based biotechnology company focusing on the development of imaging technology, announced the launch of its new 3D Tissue Imaging Services to researchers with comprehensive solutions for 3D imaging of tissues, including 3D Immunolabeling, Tissue Removal, 3D Imaging, and Quantitative Image Analysis. Traditional tissue analysis typically uses frozen or paraffin-embedded ...
Ardigen, one of the world’s leading artificial intelligence (AI) companies advancing precision medicine, has announced that it is supporting the Joint Undertaking in Morphological Profiling-Cell Painting (JUMP-CP) Consortium with its technology and expertise. The consortium of 10 leading pharmaceutical companies and two non-profit research organizations including the Broad Institute of MIT ...
ByArdigen
With years of experience in the pharmaceutical and life science sector, CD Bioparticles launched a range of near-infra-red (NIR) quantum dots that exhibit excellent optical properties and biocompatibility for biomedical imaging. Currently, CD Bioparticles has successfully synthesized a variety of NIR quantum dots, including PbS/CdS, PbS, PbSe, Ag2S, CuInS/ZnS, and CdTe/CdSe/ZnS. Quantum points ...
Quantum dots (QDs) have raised great attention due to their unique advantages. The combination of graphene and quantum dots is a huge progress for it makes the application of graphene in the biological field possible. Earlier this month, Alfa Chemistry announces the launch of a diversified quantum dots & upconverting nanoparticles for researchers from both scientific and industrial ...
SAN DIEGO, December 4, 2018 – Avelas Biosciences, Inc., a clinical-stage oncology company developing AVB-620 for real-time cancer detection, presented the initial results of the first part of its Phase II clinical trial in a poster session at this week’s San Antonio Breast Cancer Symposium (SABCS). The poster, titled “Use of a fluorescent activatable cell penetrating peptide ...
VisionGate, a clinical stage oncology pharmaceutical and diagnostics company announces two peer-reviewed poster presentations at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer (WCLC), 23-26 September in Toronto, Canada. These studies demonstrate important new morphometric detection findings of the Cell-CT™ platform and the LuCED® ...
VisionGate, a clinical stage oncology pharmaceutical and diagnostics company, today presented a breakthrough research study demonstrated its CellCT™ platform can detect subtle changes in cellular and nuclear morphology of cancer-associated cells (CACs) as a result of the cancer field effect. These non-cancerous cells have been affected by the presence of the cancer cells and have undergone ...
VisionGate, Inc., a clinical stage oncology pharmaceutical and diagnostics company, is pleased to announce that new lung cancer 3D cellular imaging research findings will be presented at the upcoming 2018 American Association of Cancer Research (AACR) annual meeting in Chicago, Illinois from April 14-18, 2018. The abstract presentation includes a breakthrough research study using the ...
VisionGate, a clinical stage oncology pharmaceutical and diagnosticscompany, is pleased to announce today the advancement of its breakthrough technology Cell-CT platform. The first shipment of commercial-capable Cell-CT systems were delivered to VisionGate’s clinical laboratory in Phoenix, Arizona earlier this year, setting the stage for the company’s advancement. “I am pleased ...